Medtronic Surges 8% on a Blowout Quarter, but Can the Biggest MedTech Company Keep This Growth Pace?

Shares jumped 7.8% to $97.75 after Medtronic delivered a first-quarter earnings report that beat expectations across the board — and did so on a day when broader markets declined, underscoring the strength of the company-specific catalyst. The question for investors: does this quarter mark the start of a sustained acceleration, or is a one-time calendar benefit flattering the numbers?

• Revenue Crushed the Street's Estimate by Over $280 Million. Medtronic reported Q1 FY27 revenue of $9.756 billion, up 13.7% both as reported and organically.

Wall Street had expected $1.39 in EPS on revenue of $9.47 billion.

Non-GAAP diluted EPS came in at $1.45, rising over 15% year-over-year — a $0.06 beat. That gap between forecast and result is wide enough to force analysts to rework their models upward.

• An Extra Week Helped, and Investors Should Adjust Accordingly. The quarter included an extra fiscal week, which the company estimates benefited Q1 organic growth by approximately $570 million. Strip that out and the underlying beat is still solid, but less dramatic. Investors should watch whether the company can sustain double-digit organic growth once that calendar tailwind disappears in coming quarters.

• Heart Devices Are the Engine Driving the Machine. Cardiovascular grew 18.9% organically, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions — the unit selling catheter-based tools used to treat irregular heartbeats. Neuroscience added 10.3%, Medical Surgical 10.0%, and Diabetes 16.9% — broad strength that gives the guidance raise credibility rather than relying on a single hot product.

• The Guidance Raise Resets the Floor for the Full Year. Medtronic raised FY27 organic revenue growth guidance to 7.25%–7.75%, up from 6.75%–7.25%.

It also lifted non-GAAP EPS guidance to $5.94–$6.00 versus the prior $5.90–$6.00 — a modest but meaningful tightening to the upside. FY27 guidance already embeds a $250 million tariff cost with no assumed refunds , meaning any trade relief could provide additional upside. The stock still trades at a forward P/E of roughly 15x, below its historical median of 15.7x and the medtech industry average of 17.7x , suggesting the market hasn't yet fully priced in this faster growth trajectory. The next test: whether Q2 proves the acceleration is real without calendar help.